Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CYTX
- CUSIP: 23283K10
- Web: www.cytori.com
Capitalization:- Market Cap: $15.42 million
- Outstanding Shares: 32,478,000
Average Prices:- 50 Day Moving Avg: $1.06
- 200 Day Moving Avg: $1.32
- 52 Week Range: $0.41 - $2.29
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.06
- P/E Growth: 0.0000
Sales & Book Value:- Annual Revenue: $10.07 million
- Price / Sales: 1.53
- Book Value: $0.31 per share
- Price / Book: 1.53
Profitability:- EBIDTA: ($18,720,000.00)
- Net Margins: -491.71%
- Return on Equity: -177.92%
- Return on Assets: -62.73%
Debt:- Debt-to-Equity Ratio: 1.28%
- Current Ratio: 0.94%
- Quick Ratio: 0.62%
Misc:- Average Volume: 672,827 shs.
- Beta: 3.04
- Short Ratio: 2.34
Frequently Asked Questions for Cytori Therapeutics (NASDAQ:CYTX)
What is Cytori Therapeutics' stock symbol?
Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."
When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?
Shares of Cytori Therapeutics reverse split on Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.
How were Cytori Therapeutics' earnings last quarter?
Cytori Therapeutics Inc (NASDAQ:CYTX) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.26) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.05. The company earned $0.60 million during the quarter, compared to analyst estimates of $2.32 million. Cytori Therapeutics had a negative net margin of 491.71% and a negative return on equity of 177.92%. The firm's quarterly revenue was down 53.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) earnings per share. View Cytori Therapeutics' Earnings History.
Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2017?
2 brokers have issued twelve-month target prices for Cytori Therapeutics' shares. Their forecasts range from $2.30 to $10.00. On average, they expect Cytori Therapeutics' share price to reach $6.15 in the next twelve months. View Analyst Ratings for Cytori Therapeutics.
What are analysts saying about Cytori Therapeutics stock?
Here are some recent quotes from research analysts about Cytori Therapeutics stock:
- 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (7/12/2017)
- 2. Maxim Group analysts commented, "With the closure of the Azaya acquisition announced this morning, we now assume a 15% market share and 35% royalty rate for the $300M European Liposomal Doxorubicin market with the first year of commercial sales in 2019. We recognize that a US fast track strategy could put Cytori's Doxorubicin in the US market (even before Europe) but for conservatism we do not assume US revenues in our model (nor do we assume Japan, or any other geographies which will likely evolve as well). We believe our 15% share and 35% royalty rates are both realistic (and market share could be conservative). The result of these changes is our valuation target now changes from $6 to $10 per share." (2/15/2017)
Who are some of Cytori Therapeutics' key competitors?
Who are Cytori Therapeutics' key executives?
Cytori Therapeutics' management team includes the folowing people:
- David M. Rickey, Independent Chairman of the Board
- Marc H. Hedrick M.D., President, Chief Executive Officer, Director
- Tiago Girao, Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
- Seijiro N. Shirahama, President , Asia Pacific
- John David Harris, Vice President, General Manager - Cell Therapy
- Jeremy Bragg Hayden, Vice President - Business Development, General Counsel
- Mark Marino M.D., Chief Medical Officer
- Gregg A. Lapointe, Director
- Richard James Hawkins, Independent Director
- Gary A. Lyons, Independent Director
How do I buy Cytori Therapeutics stock?
Shares of Cytori Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytori Therapeutics' stock price today?
One share of Cytori Therapeutics stock can currently be purchased for approximately $0.47.
MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $6.15 (1,195.01% upside) |
Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/25/2017 | B. Riley | Downgrade | Buy -> Neutral | | Low |  |
| 7/10/2017 | Maxim Group | Set Price Target | Buy | $10.00 | High | |
| 6/28/2016 | Roth Capital | Reiterated Rating | Buy | $11.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Cytori Therapeutics (NASDAQ:CYTX)Earnings History by Quarter for Cytori Therapeutics (NASDAQ CYTX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/11/2017 | Q1 2017 | ($0.31) | ($0.26) | $2.32 million | $0.60 million | View | N/A | |
| 3/23/2017 | Q4 16 | ($0.23) | ($0.24) | $3.36 million | $1.50 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.24) | ($0.26) | $2.85 million | $2.61 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.39) | ($0.43) | $2.50 million | $1.10 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.03) | ($0.41) | $2.05 million | $2.90 million | View | Listen | |
| 3/3/2016 | Q4 | ($0.04) | ($0.03) | $2.90 million | $1.56 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.06) | ($0.04) | $5.27 million | $2.48 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.03) | ($0.03) | $2.50 million | $1.60 million | View | N/A | |
| 5/11/2015 | Q115 | ($0.07) | ($0.07) | $2.44 million | $0.90 million | View | Listen | |
| 3/12/2015 | Q4 14 | ($0.08) | ($0.08) | $3.10 million | $2.47 million | View | N/A | |
| 11/6/2014 | Q3 2014 | ($0.09) | ($0.12) | $4.31 million | $1.10 million | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.11) | ($0.15) | $2.76 million | $0.94 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.14) | ($0.14) | $2.87 million | $1.03 million | View | N/A | |
| 3/12/2014 | Q413 | ($0.12) | ($0.14) | $4.37 million | $2.71 million | View | N/A | |
| 11/7/2013 | Q313 | ($0.11) | ($0.08) | $3.17 million | $8.70 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.13) | ($0.16) | $2.88 million | $6.00 million | View | N/A | |
| 5/9/2013 | Q1 2013 | ($0.16) | ($0.11) | | | View | N/A | |
| 11/8/2012 | Q312 | ($0.15) | ($0.19) | $2.25 million | $1.31 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)2017 EPS Consensus Estimate: ($0.77)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
| Q2 2017 | 1 | ($0.25) | ($0.25) | ($0.25) |
| Q3 2017 | 1 | ($0.12) | ($0.12) | ($0.12) |
| Q4 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
(Data provided by Zacks Investment Research)
Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cytori Therapeutics (NASDAQ:CYTX)Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 8.65%
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/10/2016 | John David Harris | VP | Buy | 2,500 | $2.03 | $5,075.00 | |
| 6/14/2016 | Gail K Naughton | Director | Buy | 1,000 | $2.10 | $2,100.00 | |
| 5/13/2016 | John David Harris | VP | Buy | 2,000 | $2.71 | $5,420.00 | |
| 3/9/2016 | David Rickey | Director | Buy | 150,000 | $0.19 | $28,500.00 | |
| 9/3/2015 | Tommy G Thompson | Director | Buy | 25,449 | $0.37 | $9,416.13 | |
| 9/2/2015 | Jeremy B Hayden | VP | Buy | 8,200 | $0.36 | $2,952.00 | |
| 8/28/2015 | David Rickey | Director | Buy | 56,000 | $0.31 | $17,360.00 | |
| 8/28/2015 | Marc H Hedrick | CEO | Buy | 11,200 | $0.31 | $3,472.00 | |
| 8/27/2015 | David Rickey | Director | Buy | 75,000 | $0.31 | $23,250.00 | |
| 8/21/2015 | David Rickey | Director | Buy | 50,000 | $0.38 | $19,000.00 | |
| 8/21/2015 | Marc H Hedrick | CEO | Buy | 5,000 | $0.38 | $1,900.00 | |
| 8/20/2015 | Marc H Hedrick | CEO | Buy | 10,000 | $0.40 | $4,000.00 | |
| 8/19/2015 | David Rickey | Director | Buy | 48,600 | $0.39 | $18,954.00 | |
| 8/19/2015 | Steven Kesten | VP | Buy | 6,000 | $0.39 | $2,340.00 | |
| 8/18/2015 | David Rickey | Director | Buy | 51,400 | $0.39 | $20,046.00 | |
| 8/18/2015 | Marc H Hedrick | CEO | Buy | 10,000 | $0.39 | $3,900.00 | |
| 8/18/2015 | Tiago Girao | CFO | Buy | 25,000 | $0.39 | $9,750.00 | |
| 11/13/2014 | David Rickey | Director | Buy | 20,000 | $0.47 | $9,400.00 | |
| 11/12/2014 | David Rickey | Director | Buy | 200,000 | $0.39 | $78,000.00 | |
| 11/12/2014 | Tiago Girao | CFO | Buy | 60,000 | $0.39 | $23,400.00 | |
| 11/11/2014 | Tiago Girao | CFO | Buy | 15,889 | $0.39 | $6,196.71 | |
| 6/5/2014 | David Rickey | Director | Buy | 30,000 | $2.34 | $70,200.00 | |
| 9/12/2013 | David Rickey | Director | Buy | 7,100 | $2.55 | $18,105.00 | |
| 9/11/2013 | David Rickey | Director | Buy | 2,000 | $2.58 | $5,160.00 | |
| 9/9/2013 | David Rickey | Director | Buy | 5,000 | $2.31 | $11,550.00 | |
| 9/5/2013 | David Rickey | Director | Buy | 2,000 | $2.24 | $4,480.00 | |
| 9/3/2013 | David Rickey | Director | Buy | 7,000 | $2.14 | $14,980.00 | |
| 8/30/2013 | Tommy G Thompson | Director | Buy | 5,000 | $2.14 | $10,700.00 | |
| 12/19/2012 | Lloyd H Dean | Director | Buy | 25,000 | $2.85 | $71,250.00 | |
| 12/19/2012 | Marc H Hedrick | President | Buy | 10,000 | $2.85 | $28,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cytori Therapeutics (NASDAQ:CYTX)
Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
| Source: |
|
| Date | Headline |
|---|
 | Cytori Therapeutics (CYTX) STAR Trial of Habeo Cell Therapy in Patients with Scleroderma Doesn't Met Primary Endpoint
www.streetinsider.com - July 24 at 10:28 PM |
 | Analysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR)
finance.yahoo.com - July 24 at 5:26 PM |
 | Cytori Says STAR Trial Fails To Meet Primary Or Secondary Efficacy Endpoints
www.nasdaq.com - July 24 at 10:47 AM |
| Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma
finance.yahoo.com - July 24 at 10:47 AM |
 | Zacks Investment Research Lowers Cytori Therapeutics Inc (CYTX) to Hold
www.americanbankingnews.com - July 12 at 7:10 PM |
| Cytori Therapeutics Inc (NASDAQ:CYTX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:04 PM |
| Cytori Therapeutics (CYTX) Says AMA Approves New Category III ... - StreetInsider.com
www.streetinsider.com - July 10 at 5:39 PM |
| American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy
finance.yahoo.com - July 10 at 5:39 PM |
| Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? - Nasdaq
www.nasdaq.com - July 8 at 10:07 AM |
| Cytori Therapeutics (CYTX) Issued Key Patents for Scleroderma - StreetInsider.com
www.streetinsider.com - July 8 at 10:07 AM |
| Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock?
finance.yahoo.com - July 8 at 10:07 AM |
| Pre-Open Movers 07/06: (HSNI) (BGNE) (CYTX) Higher; (EGLT) (TAHO) (AZZ) Lower (more...)
www.streetinsider.com - July 6 at 3:16 PM |
| ETFs with exposure to Cytori Therapeutics, Inc. : July 5, 2017
finance.yahoo.com - July 5 at 6:27 PM |
| Cytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America
finance.yahoo.com - June 14 at 5:36 PM |
| Cytori Therapeutics (CYTX) Publishes Long-Term Safety Data on ... - StreetInsider.com
www.streetinsider.com - June 8 at 10:41 PM |
 | Cytori Publishes Long Term Safety Data On Technology For Breast Reconstruction
www.rttnews.com - June 8 at 10:06 AM |
| Long Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy
finance.yahoo.com - June 8 at 10:06 AM |
| ETFs with exposure to Cytori Therapeutics, Inc. : June 6, 2017
finance.yahoo.com - June 6 at 4:56 PM |
| ValuEngine Lowers Cytori Therapeutics Inc (CYTX) to Strong Sell
www.americanbankingnews.com - June 4 at 9:16 PM |
| Cytori Therapeutics Inc (CYTX) PT Set at $10.00 by Maxim Group
www.americanbankingnews.com - June 1 at 11:02 PM |
 | Cytori to Introduce Next-Generation Celution® Technology - GlobeNewswire (press release)
globenewswire.com - June 1 at 10:17 PM |
| Cytori to Introduce Next-Generation Celution® Technology
finance.yahoo.com - June 1 at 5:16 PM |
| Cytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial
finance.yahoo.com - May 31 at 9:58 AM |
| Cytori Therapeutics Inc (CYTX) Short Interest Update
www.americanbankingnews.com - May 28 at 7:16 AM |
| ETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 25 at 6:25 PM |
| Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 12:38 PM |
| Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
finance.yahoo.com - May 23 at 12:32 PM |
| Cytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor Conference
finance.yahoo.com - May 16 at 12:06 PM |
| FY2019 EPS Estimates for Cytori Therapeutics Inc Lowered by B. Riley (CYTX)
www.americanbankingnews.com - May 15 at 10:10 AM |
| B. Riley Reaffirms "Buy" Rating for Cytori Therapeutics Inc (CYTX)
www.americanbankingnews.com - May 14 at 10:14 PM |
| Cytori Therapeutics Inc (CYTX) Sees Significant Drop in Short Interest
www.americanbankingnews.com - May 13 at 7:44 AM |
| Cytori Therapeutics Inc (CYTX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 12 at 7:41 PM |
| Edited Transcript of CYTX earnings conference call or presentation 11-May-17 9:30pm GMT
finance.yahoo.com - May 12 at 5:10 PM |
| Cytori Therapeutics Inc (CYTX) Issues Earnings Results
www.americanbankingnews.com - May 12 at 3:12 PM |
| Q1 2017 Earnings Estimate for Cytori Therapeutics Inc (CYTX) Issued By B. Riley
www.americanbankingnews.com - May 12 at 7:48 AM |
| EARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q1 Earnings Report
www.rttnews.com - May 11 at 10:18 PM |
| Cytori reports 1Q loss
finance.yahoo.com - May 11 at 10:18 PM |
| Cytori Reports First Quarter 2017 Business and Financial Results
finance.yahoo.com - May 11 at 5:17 PM |
| One Year Follow Up of Cytori Cell Therapy™ in Investigator Erectile Dysfunction Trial
finance.yahoo.com - May 10 at 4:49 PM |
| Cytori Therapeutics Announces Inducement Grants for New Employees
finance.yahoo.com - May 5 at 9:53 PM |
| Cytori Therapeutics (CYTX) Receives News Sentiment Rating of 0.35
www.americanbankingnews.com - May 3 at 1:24 PM |
| Cytori to Webcast First Quarter Financial Results on May 11
finance.yahoo.com - April 27 at 5:10 PM |
| Somewhat Negative Press Coverage Somewhat Unlikely to Affect Cytori Therapeutics (CYTX) Share Price
www.americanbankingnews.com - April 24 at 2:01 PM |
| Critical Media Coverage Very Unlikely to Impact Cytori Therapeutics (CYTX) Share Price
www.americanbankingnews.com - April 21 at 7:47 AM |
| Cytori Therapeutics (CYTX) Earns Media Impact Score of 0.29
www.americanbankingnews.com - April 18 at 1:54 PM |
| Cytori Therapeutics (CYTX) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 15 at 1:21 PM |
| Cytori Therapeutics (CYTX) IDE Approved by FDA for Pilot Clinical Trial to Evaluate Cytori Cell Therapy
www.streetinsider.com - April 11 at 12:56 PM |
| Cytori Therapeutics' stock plunges toward record low after stock offering prices at deep discount
finance.yahoo.com - April 11 at 12:56 PM |
| Cytori Therapeutics Stock Sliding on Offering Price Discount
finance.yahoo.com - April 11 at 12:56 PM |
 | Cytori Therapeutics -36% after pricing 8.6M-share offering at $1.10
seekingalpha.com - April 11 at 9:51 AM |
Cytori Therapeutics (CYTX) Chart for Tuesday, July, 25, 2017
